A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study (NCT05862285)
An Open-Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Study
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this extension study is to provide continued treatment with Roche investigational medicinal product (IMP\[s\]) monotherapy or Roche IMP(s) combined with other agent(s) or comparator agent(s) for eligible participants with cancer who are still on study treatment at the time of roll-over from the parent study and who do not have access to the study treatment locally.
Who can join: Review the eligibility criteria below.
Location: GHdC Site Les Viviers — Charleroi
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (68 Sites)
Showing the first 25 of 68 sites.
- GHdC Site Les Viviers — Charleroi,
- AZ Groeninge — Kortrijk,
- UZ Leuven Gasthuisberg — Leuven,
- Princess Margaret Cancer Center — Toronto, Ontario
- Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology — Wuhan, Hubei
- First Affiliated Hospital of Medical College of Xi'an Jiaotong University — XI 'an City, Shaanxi Province, Shaanxi
- Fudan University Shanghai Cancer Center — Shanghai, Shanghai Municipality
- Beijing Cancer Hospital — Beijing,
- the First Hospital of Jilin University — Changchun,
- West China Hospital of Sichuan University — Chengdu,
- Cancer Center of Guangzhou Medical University — Guangzhou,
- Sir Run Run Shaw Hospital Zhejiang University — Hangzhou,
- Zhejiang Cancer Hospital — Hangzhou,
- Harbin Medical University Cancer Hospital — Harbin,
- The Second Affiliated Hospital of Anhui Medical University — Hefei,
- Meizhou People's Hospital — Meizhou,
- The 1st Affiliated Hospital of Nanchang Unversity — Nanchang,
- Jiangsu Province Hospital of Chinese Medicine — Nanjing,
- Fudan University Shanghai Cancer Center — Shanghai,
- Shanghai Geriatric Medical Center — Shanghai,
- The First Affiliated Hospital of Xiamen University — Xiamen,
- The First Affiliated Hospital of Xinxiang Medical University — Xinxiang,
- Henan Cancer Hospital — Zhengzhou,
- Clinica CIMCA — San José,
- ICIMED Instituto de Investigación en Ciencias Médicas — San José,
📞 Contact the Study Coordinator
Phone: (888) 662-6728
Email: global-roche-genentech-trials@gene.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cancer
- Ovarian Tissue Cryopreservation in Children — Rochester, Minnesota
- A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study — Aurora, Colorado
- Ex Onc SLED: A Study Utilizing A Weighted Sled for Horizontal Resistance Training — Pittsburgh, Pennsylvania
- An Internet-based Program to Help Cancer Survivors Manage Pain — Fort Smith, Arkansas
- Identification of Patients With Age-Related Clonal Hematopoiesis (ARCH) Among Cancer Survivors — Toronto, Ontario
- Researching the Effect of Aerobic Exercise on Cancer — Los Angeles, California
Explore by condition: All Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.